Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Azacitidine in Acute Myeloid Leukemia: NCT06664879 Clinical Landscape Report 2026
16 October 2026
NCT06664879 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCD-248 in Multiple Myeloma: NCT06668792 Clinical Landscape Report 2026
16 October 2026
NCT06668792 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06668558 Clinical Landscape Report 2026
16 October 2026
NCT06668558 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olutasidenib in Myeloid Tumor: NCT06668584 Clinical Landscape Report 2026
16 October 2026
NCT06668584 clinical landscape for Myeloid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
REGN-7945 in Multiple Myeloma: NCT06669247 Clinical Landscape Report 2026
16 October 2026
NCT06669247 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gilteritinib Fumarate in Adult Acute Myeloblastic Leukemia: NCT06667973 Clinical Landscape Report 2026
16 October 2026
NCT06667973 clinical landscape for Adult Acute Myeloblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Rapcabtagene autoleucel in Multiple Sclerosis, Chronic Progressive: NCT06675864 Clinical Landscape Report 2026
16 October 2026
NCT06675864 clinical landscape for Multiple Sclerosis, Chronic Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Decitabine/Cedazuridine in IDH2 mutation Acute Myeloblastic Leukemia: NCT06672146 Clinical Landscape Report 2026
16 October 2026
NCT06672146 clinical landscape for IDH2 mutation Acute Myeloblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
JY-231 in Systemic Lupus Erythematosus: NCT06675422 Clinical Landscape Report 2026
16 October 2026
NCT06675422 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azacitidine in Acute myeloid leukaemia with 11q23 abnormality: CTRI/2024/11/076347 Clinical Landscape Report 2026
16 October 2026
CTRI/2024/11/076347 clinical landscape for Acute myeloid leukaemia with 11q23 abnormality: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Ocrelizumab in Multiple Sclerosis: NCT06675955 Clinical Landscape Report 2026
16 October 2026
NCT06675955 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NK-010 in Lupus Nephritis: NCT06676631 Clinical Landscape Report 2026
16 October 2026
NCT06676631 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.